iPSCs (iPS Cells, Induced Pluripotent Stem Cells)
Applied StemCell’s induced pluripotent stem cell (iPSC) catalog includes well-characterized, human iPS cell lines suitable for iPSC culture applications such as genome editing for disease modeling, for differentiation into cellular lineages of choice, and drug toxicity/ efficacy screening:
- Footprint-free iPSC cells (episomal and other integration-free methods) and retroviral-reprogrammed iPSCs
- Characterized for pluripotency markers, karyotyping and differentiation potential; more characterization options are available
- Multiple donor tissues: PBMCs, fibroblasts, cord blood, adipocytes from healthy and diseased patients
- Tested for CRISPR genome editing and differentiation potential into various cell lineages
- Ideal as master iPSC cell lines to build engineered and/or panels of differentiated isogenic cell lineages
iPSC Cells, Human, Disease
iPSC-derived Neuronal Lineage Cells:
Direct Differentiation of Control ‘Master” iPSC Line, ASE-9209 into the Three Germ Layers
Figure 1. Immunofluorescent staining for lineage-specific biomarkers of three germ layers after direct differentiation of hiPSCs. Control hiPSC line, ASE-9209 (female, fibroblasts) were differentiated to specific lineages of the germ layers using well-established and optimized protocols. Immunostaining for biomarkers of each lineage was performed to confirm lineage commitment. Ectoderm markers: neuronal lineage markers, PAX6 (green), b-III Tubulin (red); Mesoderm markers: Brachyury (green) and GATA4 (red); Endoderm markers: SOX17 (green) and FOXA2 (red); DAPI (blue) was used to stain for nuclear localization.
Dopaminergic neurons differentiated from control iPSC line ASE-9109
Figure 2. Dopaminergic neurons differentiated from male cord blood control iPSC line ASE-9109. Immunocytochemical analysis of neuronal marker, Tuj1 (neuronal type β III tubulin; green); dopamine neuron marker, TH (tyrosine hydroxylase; red); and nuclear marker, DAPI (blue).
Induced Pluripotent stem cells (iPSCs) are a type of embryonic-like pluripotent stem cells that is reprogrammed from adult somatic cells derived from healthy or diseased patients such as peripheral blood mononuclear cells (PBMCs), fibroblasts, cord blood cells, urine, etc. These pluripotent stem cells express stem cell markers, have the ability to propagate indefinitely and to differentiate into any type of cell in the body. They thus provide a limitless supply of patient-derived samples to develop in vitro preclinical models of diseases especially hard-to-source samples from patients, that represent the genetic and epigenetic features of a disease better while circumventing the ethical and sourcing issues associated with embryonic stem cells (ESCs). As well, iPSCs are amenable to genome editing which has been a stumbling block for developing research models using primary cells lines. Such genome edited iPSCs can be differentiated into various somatic lineages for precise and predictive disease modeling. In the decade since their discovery, iPSC cell lines have revolutionized in vitro (cell culture)-based research and have proven to be an invaluable tool in making translational research more reliable. These cells have tremendous potential as cell replacement therapy in regenerative medicine and extensive research and resources are being put into understanding iPSCs to make safe and effective therapies.
Applied StemCell’s provides a variety of human iPS cells from different donors and tissue sources to fit a wide-variety of applications. Our iPSC cell lines are generated primarily using footprint-free, reprogramming methods (episomal and other non-integrating techniques) by transient expression of human transcription factors that initiate the reprogramming process. The single cell clones of the resulting iPSCs are carefully selected using morphological criteria without the use of fluorescent markers or drug selection. These iPSCs are then characterized extensively for expression of pluripotency markers, karyotyping, directed-differentiation into various cell lineages and the capability for CRISPR/Cas9 genome editing. We also provide optional in-depth characterization options such as whole genome sequencing, RNA-seq, STR analysis (of parental cell and iPSC), high resolution karyotyping using array analysis, EB formation, copy number variation (CNV) and HLA typing, as suited for your requirements.
Some of our control human iPSC cell lines that are ideal as master iPSCs include:
- These iPSCs have proven differentiation capability to neural lineage cells using easy and optimized protocols
- Suitable for genetic modification using CRISPR/Cas9 and TARGATT™: Neural Disease Specific KO iPSCs, Knock-in Reporter iPSC, and TARGATT Knock-in iPSC
- They serve as isogenic controls for engineered cell lines
- Multiple donors and tissue sources provide a broad genetic background for basic research, drug and toxicity screening applications
We also have a human control iPSC lines reprogrammed from fibroblasts using retroviral methods: ASE-9101
Applied StemCell is recognized leader in stem cell and genome editing technologies, and is a member of the National Institute of Standards and Technology (NIST) Genome Editing Consortium.
Control iPSC Lines:
- Tanaka, H., Homma, H., Fujita, K., Kondo, K., Yamada, S., Jin, X., ... & Atsuta, N. (2020). YAP-dependent necrosis occurs in early stages of Alzheimer’s disease and regulates mouse model pathology. Nature Communications, 11(1), 1-22.
- Su, S., Guntur, A. R., Nguyen, D. C., Fakory, S. S., Doucette, C. C., Leech, C., ... & Sims-Lucas, S. (2018). A renewable source of human beige adipocytes for development of therapies to treat metabolic syndrome. Cell reports, 25(11), 3215-3228.
- Lizarraga, S. B., Maguire, A. M., Ma, L., van Dyck, L. I., Wu, Q., Nagda, D., ... & Cowen, M. H. (2018). Human neurons from Christianson syndrome iPSCs reveal allele-specific responses to rescue strategies. bioRxiv, 444232.
- Tanaka, H., Kondo, K., Chen, X., Homma, H., Tagawa, K., Kerever, A., ... & Fujita, K. (2018). The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology. Molecular Psychiatry, 1.
- Kavyasudha C., Macrin D., ArulJothi K.N., Joseph J.P., Harishankar M.K., Devi A. (2018) Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale. In: Advances in Experimental Medicine and Biology. Springer, New York, NY. https://doi.org/10.1007/5584_2018_173.
- Lin, Y., Linask, K. L., Mallon, B., Johnson, K., Klein, M., Beers, J., ... & Zou, J. (2017). Heparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin‐Free Medium, Enabling Consistent Manufacture of Cardiomyocytes. Stem cells translational medicine, 6(2), 527-538.